DaVita lifts lower end of 2026 profit forecast, shares fall
DVA•DaVita raised the lower end of its 2026 adjusted profit-per-share forecast to $14.30 from $14.10, keeping the upper end at $15.20. It reported third-quarter adjusted profit of $3.82 per share and revenue of $3.58 billion, both above estimates.
1. Forecast and results
DaVita expects 2026 profit per share of $14.30 to $15.20, compared with its prior outlook of $14.10 to $15.20. Third-quarter adjusted profit per share was $3.82, versus analysts’ estimate of $3.61, while revenue was $3.58 billion, compared with an estimate of $3.51 billion.
2. 2027 outlook
Executives said on a post-earnings call they expect volume growth in 2027 to outpace 2026 levels, while cautioning that revenue per treatment could face pressure from a less favorable commercial mix, driven largely by Affordable Care Act plans. Lower pharmaceutical costs could provide some offset in 2027.
3. Share repurchase
DaVita paid about $69 million to repurchase 382,563 shares from Berkshire Hathaway, which retained a 45% stake in the dialysis provider. Shares fell 7.4% to $179 in extended trading.
